◆英語タイトル:NicOx SA (COX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011483
◆発行会社(調査会社):
GlobalData
◆発行日:2017年12月22日
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
NicOx SA (NicOx) is an pharmaceutical company that develops ophthalmic portfolio of therapies and diagnostic tools. The company offers ophthalmic products which include AdenoPlus, AzaSite, BromSite, Xailin, Vesneo, next generation NO-donors and Syk and JAK inhibitors, and others. It offers products in the therapeutic areas of NO-donating compounds, based on a strong research platform which creates new molecular entities. NicOx operates research centers in Italy that works on R&D studies covering various therapy areas such as cardiovascular, inflammation and ophthalmology. The company operates in Germany, the UK, France, Italy and the US. NicOx is headquartered in Nice, France.
NicOx SA (COX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NicOx SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
NicOx SA, Medical Equipment Deals By Type, 2011 to YTD 2017 6
NicOx SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
NicOx SA, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
NicOx SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
NicOx SA, Medical Equipment, Deal Details 10
Partnerships 10
Nicox Enters into Licensing Agreement with OptiMed for AdenoPlus and Xailin 10
NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus 11
Nicox and Re-Vana Therapeutics Enter into Research Agreement 12
NicOx Enters into Co-Marketing Agreement with Nitto Medic for AdenoPlus 13
NicOx Amends Licensing Agreement with Rapid Pathogen Screening for AdenoPlus 14
Equity Offering 15
NicOx Raises USD31 Million in Private Placement of Shares 15
Nicox to Raise USD20 Million in Private Placement of Shares 16
Acquisition 17
NicOx Acquires Aciex Therapeutics 17
NicOx Acquires Doliage for USD6.5 Million 18
NicOx Completes Acquisition Of Eupharmed For US$8 Million 19
NicOx SA – Key Competitors 21
NicOx SA – Key Employees 22
NicOx SA – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Sep 08, 2017: Nicox first half 2017 business and financial update 24
Apr 27, 2017: Nicox first quarter 2017 business update and cash position 25
Mar 31, 2017: Nicox: Business Update and 2016 Financial Results 26
Sep 22, 2016: Nicox first half 2016 business and financial update 28
May 10, 2016: Nicox first quarter 2016 financial and business update 30
Apr 15, 2016: Nicox: 2015 Financial Results and Business Update 31
Feb 25, 2016: Nicox reports strong revenue growth in 2015 and provides corporate update 33
Corporate Communications 34
May 17, 2017: Mrs. Lauren P. Silvernail appointed to Nicox Board of Directors 34
May 17, 2017: Ms. Lauren P. Silvernail appointed to Nicox Board of Directors 35
Other Significant Developments 36
Nov 03, 2017: Nicox Highlights VYZULTA approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives 36
Oct 24, 2017: Nicox Provides Third Quarter 2017 Business Update and Cash Position 38
Sep 08, 2017: Nicox first half 2017 business and financial update 40
Oct 11, 2016: Nicox third quarter 2016 business update and cash position 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
List of Tables
NicOx SA, Medical Equipment, Key Facts, 2016 2
NicOx SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
NicOx SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
NicOx SA, Medical Equipment Deals By Type, 2011 to YTD 2017 6
NicOx SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
NicOx SA, Deals By Market, 2011 to YTD 2017 8
NicOx SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Nicox Enters into Licensing Agreement with OptiMed for AdenoPlus and Xailin 10
NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus 11
Nicox and Re-Vana Therapeutics Enter into Research Agreement 12
NicOx Enters into Co-Marketing Agreement with Nitto Medic for AdenoPlus 13
NicOx Amends Licensing Agreement with Rapid Pathogen Screening for AdenoPlus 14
NicOx Raises USD31 Million in Private Placement of Shares 15
Nicox to Raise USD20 Million in Private Placement of Shares 16
NicOx Acquires Aciex Therapeutics 17
NicOx Acquires Doliage for USD6.5 Million 18
NicOx Completes Acquisition Of Eupharmed For US$8 Million 19
NicOx SA, Key Competitors 21
NicOx SA, Key Employees 22
NicOx SA, Subsidiaries 23